The DIA 2018 Global Annual Meeting brings together thousands of innovators from around the globe.
Cardiac Safety in Drug Development and the Critical Role of Public-Private Partnerships: The Cardiac Safety Research Consortium Model
Rick Turner, DrSc, PhD
Turner Consulting and Communications LLC, United States
This session will discuss how the Cardiac Safety Research Consortium’s collaborative, precompetitive approach has significantly advanced the field of cardiac safety in medical product development. Industry, academia, and regulatory perspectives will be provided.
Learning Objective : Discuss the concept and implementation of Public-Private Partnerships; Recognize the importance of cardiac safety considerations throughout new drug development; Describe new approaches to regulatory science in cardiac safety.
The Cardiac Safety Research Consortium: Current Accomplishments and Future Goals
Mitchell W. Krucoff, MD
Professor of Medicine/Cardiology
Duke University, United States
New Approaches to Regulatory Science in Cardiac Safety
Norman Stockbridge, MD, PhD
Director, Division of Cardiovascular and Renal Products, OND, CDER
FDA, United States
The Comprehensive In-Vitro Proarrhythmia Assay (CiPA)
Philip T. Sager, MD
Stanford University, United States